Kybernin P (Antithrombin Iii)

Antithrombin III in Kybernin P binds to thrombin and several activated clotting factors, accelerating their inactivation. This reduces fibrin formation and helps control bleeding or prevent unwanted clot formation during surgical interventions.

The prescribed dose of Kybernin P is determined by the treating physician based on the patient’s antithrombin activity level, weight, and clinical condition. Dosing regimens are individualized and not standardized.

Safety data for Kybernin P in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Kybernin P, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Kybernin P is a specific antithrombin replacement, whereas most anticoagulants (e.g., heparin, warfarin, DOACs) act by inhibiting clotting factors indirectly. Kybernin P is particularly indicated for patients with antithrombin deficiency, offering targeted restoration of physiological anticoagulation rather than broad‑spectrum inhibition.

Kybernin P must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Kybernin P is given as an intravenous infusion. The rate and duration of infusion are determined by the prescribing clinician, who will monitor antithrombin activity levels and clinical response during administration.

The most serious risks include severe allergic reactions such as anaphylaxis, unexpected major bleeding, and rare thrombotic events despite therapy. Patients should be observed closely during and after infusion for any signs of these complications.

Kybernin P is contraindicated in patients with known hypersensitivity to antithrombin III products or any component of the formulation. It should also be avoided in individuals with uncontrolled active bleeding where additional anticoagulation could worsen the condition.